Mode
Text Size
Log in / Sign up
Phase 2 N=99 Treatment

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

Pancreatic Tumours · Midgut Neuroendocrine Tumours

Enrolled (actual)
99
Serious AEs
18.2%
Results posted
Dec 2020
Primary outcome: Primary: Median Progression Free Survival (PFS) — 5.6; 8.3 months

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Lanreotide autogel 120 mg (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Ipsen
Primary completion
Oct 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Median Progression Free Survival (PFS)
5.6; 8.3
SECONDARY
Median Time to Progression
5.6; 8.7
SECONDARY
Percentage of Subjects Alive and Progression Free
93.3; 91.8; 64.4; 65.3; 37.8; 59.2
SECONDARY
Overall Survival
NA; NA
SECONDARY
Objective Response Rate (ORR)
0.0; 0.0; 0.0; 0.0; 0.0; 0.0
SECONDARY
Disease Control Rate (DCR)
43.8; 58.8; 22.9; 33.3
SECONDARY
Best Overall Response Rate
0.0; 0.0; 0.0; 3.9; 66.7; 68.6
SECONDARY
Median Duration of Stable Disease
8.3; 13.8
SECONDARY
Factors Associated With PFS
0.96; 1.54; 0.68; 0.90; 1.04; 2.14
SECONDARY
Mean Change From Baseline in Number of Stools and Flushing Episodes
1.0; -1.0; -1.2; 0.7; -1.0; 3.4
SECONDARY
Mean Change From Baseline in QoL Measured Using EORTC, QLQ-C30 v3.0 (Global Health Status Sub-score)
-0.38; -1.33; -0.89
SECONDARY
Mean Change From Baseline in EQ-5D-5L v1.0 Questionnaire (Descriptive System)
-0.04; 0.00; -0.02
SECONDARY
Mean Change From Baseline in EQ-5D-5L v1.0 Questionnaire (VAS)
-1.90; -1.76; -1.83
SECONDARY
Mean Change From Baseline in QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21; 2006)
-0.53; -5.09; -2.96; -3.49; -2.78; -3.11
SECONDARY
Mean Change From Baseline in Nonspecific Tumour Biomarkers
0.205; 0.370; 0.03; -0.49; -0.42; 3.90
SECONDARY
Mean Change From Baseline in PanNet Specific Tumour Biomarkers: Pancreatic Polypeptide, Gastrin
82.7; -9.8
SECONDARY
Mean Change From Baseline in PanNet Specific Tumour Biomarkers: Glucagon
5.5

Summary

This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.

Eligibility Criteria

Inclusion Criteria

  • Histopathologically confirmed, grade 1 or 2, metastatic or locally advanced, unresectable pNET (pNET cohort) or midgut NET (midgut cohort) with or without hormone related syndromes, with a proliferation index (Ki67) ≤20%.
  • Positive somatostatin receptors type 2
  • Progression as assessed by an independent central reviewer according to RECIST v1.0 while receiving first line treatment with lanreotide Autogel® at a standard dose of 120 mg every 28 days for at least 24 weeks

Exclusion Criteria

  • Grade 3 or rapidly progressive (within 12 weeks) NET
  • Any NET other than pancreatic and midgut
  • Previous treatment with any antitumour agent for NET other than lanreotide Autogel® 120 mg every 28 days. Exception made of prior treatment with Octreotide at standard dose stopped for other reason than disease progression.
  • Symptomatic gallbladder lithiasis at screening echography or history of cholelithiasis with no cholecystectomy since then.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02651987). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search